High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia
The BLM gene belongs to the RecQ helicase family and has been implicated in the maintenance of genomic stability. Its homozygous germline inactivation causes Bloom syndrome, a severe genetic disorder characterized by growth retardation, impaired fertility and highly elevated cancer risk. We hypothes...
Saved in:
Published in | International journal of cancer Vol. 130; no. 12; pp. 2867 - 2873 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
15.06.2012
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0020-7136 1097-0215 1097-0215 |
DOI | 10.1002/ijc.26342 |
Cover
Summary: | The BLM gene belongs to the RecQ helicase family and has been implicated in the maintenance of genomic stability. Its homozygous germline inactivation causes Bloom syndrome, a severe genetic disorder characterized by growth retardation, impaired fertility and highly elevated cancer risk. We hypothesized that BLM is a candidate gene for breast cancer (BC) predisposition. Sequencing of its entire coding region in 95 genetically enriched Russian BC patients identified two heterozygous carriers of the c.1642 C>T (Q548X) mutation. The extended study revealed this allele in 17/1,498 (1.1%) BC cases vs. 2/1,093 (0.2%) healthy women (p = 0.004). There was a suggestion that BLM mutations were more common in patients reporting first‐degree family history of BC (6/251 (2.4%) vs. 11/1,247 (0.9%), p = 0.05), early‐onset cases (12/762 (1.6%) vs. 5/736 (0.7%), p = 0.14) and women with bilateral appearance of the disease (2/122 (1.6%) vs. 15/1376 (1.1%), p = 0.64). None of the BLM‐associated BC exhibited somatic loss of heterozygosity at the BLM gene locus. This study demonstrates that BLM Q548X allele is recurrent in Slavic subjects and may be associated with BC risk. |
---|---|
Bibliography: | ArticleID:IJC26342 ark:/67375/WNG-5155V7RD-M istex:8562C62B9335F08046FEDF234D7C546C23ECC41B Federal Agency for Science and Innovations - No. 02.740.11.0780 the Russian Federation for Basic Research - No. 11-04-00250; No. 10-04-92601; No. 10-04-00962 Royal Society - No. JP090615 Sigrid Jusélius, Finnish Medical Foundations Commission of the European Communities - No. PITN-GA-2009-238132 Government of Moscow - No. 15/11 Tel: [+7‐812‐5968951], Fax: [+7‐812‐5968947] ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0020-7136 1097-0215 1097-0215 |
DOI: | 10.1002/ijc.26342 |